What is HC Wainwright’s Estimate for REGENXBIO Q3 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for REGENXBIO in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.61) per share for the quarter, down from their prior forecast of ($0.22). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($3.63) EPS.

Other equities research analysts have also recently issued reports about the company. Barclays initiated coverage on REGENXBIO in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective for the company. Leerink Partners upped their target price on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Wall Street Zen downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Finally, Stifel Nicolaus upped their price objective on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.80.

REGENXBIO Stock Down 4.0%

RGNX opened at $8.50 on Thursday. The stock’s 50 day moving average price is $13.27 and its two-hundred day moving average price is $11.41. The firm has a market capitalization of $430.27 million, a P/E ratio of -2.45 and a beta of 1.05. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $16.19.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently bought and sold shares of RGNX. Inceptionr LLC lifted its holdings in shares of REGENXBIO by 43.5% during the 4th quarter. Inceptionr LLC now owns 17,440 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 5,286 shares during the period. Deutsche Bank AG raised its position in REGENXBIO by 0.8% in the fourth quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after purchasing an additional 1,527 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its position in REGENXBIO by 24.0% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 12,676 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 2,455 shares in the last quarter. Fox Run Management L.L.C. bought a new position in REGENXBIO during the fourth quarter worth about $252,000. Finally, Cerity Partners LLC boosted its holdings in REGENXBIO by 9.5% during the fourth quarter. Cerity Partners LLC now owns 71,488 shares of the biotechnology company’s stock valued at $1,029,000 after purchasing an additional 6,211 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Clear Street says RGNX still has over 300% upside despite the FDA pushback, arguing the longer‑term value of REGENXBIO’s AAV platforms and pipeline could dwarf the near‑term setback. Clear Street: RGNX upside
• Positive Sentiment: Morgan Stanley cut its price target from $25 to $18 but kept an “overweight” rating, signaling they still see roughly 110%+ upside from current levels and that the FDA decision may be a remediable regulatory/clinical issue rather than terminal for the franchise. Morgan Stanley coverage
• Positive Sentiment: Chardan Capital trimmed its target slightly (from $52 to $50) but maintained a “buy” rating, implying very large upside — Chardan’s stance supports investor hopes that pipeline value beyond RGX‑121 still justifies a high multiple. Chardan Capital coverage
• Negative Sentiment: The FDA declined to approve RGX‑121 for Hunter syndrome, a direct setback to REGENXBIO’s lead rare‑disease program and near‑term revenue/catalyst expectations; the decision spurred sharp share declines and increased regulatory uncertainty. FDA declines to approve RGX‑121
• Negative Sentiment: Multiple reports note the FDA rejection materially clouds the commercial path and prompted immediate downside pressure; investors should expect elevated volatility while REGENXBIO evaluates next steps (appeal, additional data, or new submission strategy). PharmaLetter: FDA rejection impact

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.